Physician profile
Carolyn Oconor
NPI 1437185972
$3,076.67
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $174 · 2021: $381 · 2022: $857 · 2023: $942 · 2024: $30.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $464.18 | 2019-2023 | Wegovy, Saxenda, Ozempic |
| Pfizer INC. | $277.94 | 2019-2023 | |
| Abbvie INC. | $266.34 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $259.58 | 2019-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Abbott Laboratories | $208.48 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $195.90 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $183.89 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $153.88 | 2022-2023 | Quviviq |
| Horizon Therapeutics Plc | $148.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $135.55 | 2019-2023 | Breztri, Farxiga |
| Ascensia Diabetes Care US INC. | $123.24 | 2023 | |
| Amgen INC. | $104.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.76 | 2021-2023 | Vpriv |
| Optinose US, INC. | $87.64 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.92 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $49.08 | 2022-2023 | Veozah |
| Sanofi Pasteur INC. | $35.89 | 2019-2023 | |
| Axogen | $24.11 | 2022 | |
| Bausch Health US, LLC | $23.87 | 2023 | Aplenzin |
| Exact Sciences Corporation | $21.95 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $19.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.80 | 2022 | |
| Genzyme Corporation | $15.87 | 2021 | |
| Philips North America LLC | $14.96 | 2022 | |
| Allergan, INC. | $14.95 | 2019 | |
| Seqirus USA INC | $14.80 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Biohaven Pharmaceuticals, INC. | $14.43 | 2021 | |
| Medtronic USA, INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Oconor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.